NCT06778512Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics
Source: ClinicalTrials.gov · Last updated 16 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 12 Jan 2025
- Start date
- 1 Jun 2019
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Diseases
- Lung cancer
- NCT number
- NCT06778512
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 1 Jun 2019 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with obstructive lesions such as airway or esophageal stenosis;
- (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Other illness
- Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
Other
- Poor preoperative pulmonary function cooperation or missing reports;
- Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
- The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
- Coexisting with other severe functional impairments;
Who the study is looking for
- Signing of the informed consent form;
- Male or female, aged 18-75 years;
- Patients with lung nodules confirmed by CT examination;
- Good preoperative pulmonary function cooperation and complete reporting;
- Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
- The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.
Age in the registry: 18 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the First Affiliated of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.